INBX - Inhibrx: Potential To Move To Registration Study With INBRX-101
- Positive results have been released thus far from a phase 1 study using INBRX-101 for the treatment of patients with Alpha-1 Antitrypsin Deficiency.
- It is expected that the Alpha-1 Antitrypsin Deficiency Augmentation therapy market could reach $1.95 billion by 2026.
- If FDA gives green light to Inhibrx, then it should be able to initiate a pivotal registration study using INBRX-101 for patients with Alpha-1 Antitrypsin Deficiency 2nd half of 2022.
- INBRX-109, INBRX-106, INBRX-105, and INBRX-121 are 4 additional drugs in the pipeline being advanced as treatments for cancer; All 4 of these drugs plus INBRX-101 utilize the company's Single-domain antibody technology platform.
For further details see:
Inhibrx: Potential To Move To Registration Study With INBRX-101